Psilocybin-assisted therapy is legal in three states, but access has so far been limited and expensive. In the billion-dollar race to commercialize psychedelic medicine, psilocybin, a naturally ...

A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...

An analysis of major depressive disorder, covering diagnostic criteria, prevalence statistics across demographics, and ...

Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.

Dr Suchitra Sundaram reflects on time limited venetoclax combinations, next generation non covalent BTK inhibitors, and novel triplet regimens.

Two years after premiering a 13-minute documentary about three eczema patients, Abbvie has again teamed with branded entertainment firm Passion Point Collective, this time for a 16-minute documentary ...

Terry Evans is in a paid partnership with Lilly and has been compensated for his time. Like many parents back in the 1990s, Terry Evans of Huntington Beach, Calif., was wrapped up in his job and ...